PIS
NVCR icon

POM Investment Strategies’s NovoCure NVCR Stock Holding History

POM Investment Strategies’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100
Closed -$2.98K – 313
2024
Q4 		$2.98K Hold
100
– – ﹤0.01% 250
2024
Q3 		$1.56K Hold
100
– – ﹤0.01% 242
2024
Q2 		$1.71K Hold
100
– – ﹤0.01% 278
2024
Q1 		$1.56K Hold
100
– – ﹤0.01% 207
2023
Q4 		$1.49K Buy
+100
New +$1.34K ﹤0.01% 198

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

POM Investment Strategies's NVCR Position: Q1 2025 in Review

POM Investment Strategies sold out of NovoCure (NVCR) in Q1 2025, closing a stake of 100 shares — an estimated $2.98K sold.

POM Investment Strategies first reported a position in NVCR in Q4 2023 and held it in 5 quarters. The position peaked at $2.98K in Q4 2024. 228 funds tracked by Wall St. Rank hold NVCR as of Q1 2025.

  • POM Investment Strategies reported no remaining NovoCure position as of Q1 2025 after selling out during the quarter.
  • POM Investment Strategies sold 100 NovoCure shares in Q1 2025, an estimated $2.98K.
  • POM Investment Strategies first reported a position in NovoCure in Q4 2023 and held it in 5 quarters.
  • POM Investment Strategies's NovoCure position peaked at $2.98K in Q4 2024.
  • 228 funds tracked by Wall St. Rank held NovoCure as of Q1 2025.

Based on POM Investment Strategies's 13F filing for Q1 2025, filed 30 Apr 2025.